

Romina Moavero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5363013/publications.pdf>

Version: 2024-02-01

98
papers

4,015
citations

126708

33
h-index

128067

60
g-index

101
all docs

101
docs citations

101
times ranked

3718
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway. <i>Epilepsy and Behavior</i> , 2022, 131, 107713.	0.9	10
2	Sleep disorders and neuropsychiatric disorders in a pediatric sample of tuberous sclerosis complex: a questionnaire-based study. <i>Sleep Medicine</i> , 2022, 89, 65-70.	0.8	5
3	Subacute Sclerosing Panencephalitis in Children: The Archetype of Non-Vaccination. <i>Viruses</i> , 2022, 14, 733.	1.5	7
4	Questionnaire-based assessment of sleep disorders in an adult population of Tuberous Sclerosis Complex. <i>Sleep Medicine</i> , 2022, 92, 81-87.	0.8	1
5	Pediatric Neuromyelitis Optica Spectrum Disorder: Case Series and Literature Review. <i>Life</i> , 2022, 12, 19.	1.1	3
6	Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the <scp>EPISTOP</scp> Trial. <i>Annals of Neurology</i> , 2021, 89, 304-314.	2.8	137
7	Features and Management of New Daily Persistent Headache in Developmental-Age Patients. <i>Diagnostics</i> , 2021, 11, 385.	1.3	9
8	Surgery for drug-resistant tuberous sclerosis complex-associated epilepsy: who, when, and what. <i>Epileptic Disorders</i> , 2021, 23, 53-73.	0.7	17
9	Early epileptiform EEG activity in infants with tuberous sclerosis complex predicts epilepsy and neurodevelopmental outcomes. <i>Epilepsia</i> , 2021, 62, 1208-1219.	2.6	19
10	Clinical and neuroimaging characteristics of MOG autoimmunity in children with acquired demyelinating syndromes. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102837.	0.9	7
11	Use of Nutraceutical Ingredient Combinations in the Management of Tension-Type Headaches with or without Sleep Disorders. <i>Nutrients</i> , 2021, 13, 1631.	1.7	5
12	Results of quantitative EEG analysis are associated with autism spectrum disorder and development abnormalities in infants with tuberous sclerosis complex. <i>Biomedical Signal Processing and Control</i> , 2021, 68, 102658.	3.5	7
13	Sleep Disorders in Pediatric Migraine: A Questionnaire-Based Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 3575.	1.0	8
14	Truths and Myths in Pediatric Migraine and Nutrition. <i>Nutrients</i> , 2021, 13, 2714.	1.7	12
15	Case Report: Migralepsy: The Two-Faced Janus of Neurology. <i>Frontiers in Neurology</i> , 2021, 12, 711858.	1.1	2
16	Neuropsychological Sequelae, Quality of Life and Adaptive Behavior in Children and Adolescents with Anti-NMDAR Encephalitis: A Narrative Review. <i>Brain Sciences</i> , 2021, 11, 1387.	1.1	1
17	Benign Intracranial Hypertension Due to Hypoparathyroidism: A Case Report. <i>Frontiers in Neurology</i> , 2021, 12, 818638.	1.1	2
18	How to Assess the Headache-Sleep Disorders Comorbidity in Children and Adolescents. <i>Journal of Clinical Medicine</i> , 2021, 10, 5887.	1.0	2

#	ARTICLE	IF	CITATIONS
19	Migraine and Its Equivalents: What Do They Share? A Narrative Review on Common Pathophysiological Patterns. <i>Life</i> , 2021, 11, 1392.	1.1	4
20	High Intellectual Potential and High Functioning Autism: Clinical and Neurophysiological Features in a Pediatric Sample. <i>Brain Sciences</i> , 2021, 11, 1607.	1.1	4
21	Anxiety, Depression, and Body Weight in Children and Adolescents With Migraine. <i>Frontiers in Psychology</i> , 2020, 11, 530911.	1.1	11
22	Is autism driven by epilepsy in infants with Tuberous Sclerosis Complex?. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1371-1381.	1.7	23
23	Medication Overuse Withdrawal in Children and Adolescents Does Not Always Improve Headache: A Cross-Sectional Study. <i>Frontiers in Neurology</i> , 2020, 11, 823.	1.1	5
24	I stay at home with headache. A survey to investigate how the lockdown for COVID-19 impacted on headache in Italian children. <i>Cephalalgia</i> , 2020, 40, 1459-1473.	1.8	43
25	Prediction of Neurodevelopment in Infants With Tuberous Sclerosis Complex Using Early EEG Characteristics. <i>Frontiers in Neurology</i> , 2020, 11, 582891.	1.1	19
26	Autism and Epilepsy in Patients With Tuberous Sclerosis Complex. <i>Frontiers in Neurology</i> , 2020, 11, 639.	1.1	36
27	TSC2 pathogenic variants are predictive of severe clinical manifestations in TSC infants: results of the EPISTOP study. <i>Genetics in Medicine</i> , 2020, 22, 1489-1497.	1.1	51
28	Event-Related Potentials in ADHD Associated With Tuberous Sclerosis Complex: A Possible Biomarker of Symptoms Severity?. <i>Frontiers in Neurology</i> , 2020, 11, 546.	1.1	8
29	Long-term use of mTORC1 inhibitors in tuberous sclerosis complex associated neurological aspects. <i>Expert Opinion on Orphan Drugs</i> , 2020, 8, 215-225.	0.5	1
30	Tolerability of Palmitoylethanolamide in a Pediatric Population Suffering from Migraine: A Pilot Study. <i>Pain Research and Management</i> , 2020, 2020, 1-7.	0.7	18
31	Prophylactic Treatment of Pediatric Migraine: Is There Anything New in the Last Decade?. <i>Frontiers in Neurology</i> , 2019, 10, 771.	1.1	27
32	Early Clinical Predictors of Autism Spectrum Disorder in Infants with Tuberous Sclerosis Complex: Results from the EPISTOP Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 788.	1.0	42
33	A step-wise approach for establishing a multidisciplinary team for the management of tuberous sclerosis complex: a Delphi consensus report. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 91.	1.2	36
34	Cyclic vomiting syndrome and benign paroxysmal torticollis are associated with a high risk of developing primary headache: A longitudinal study. <i>Cephalalgia</i> , 2019, 39, 1236-1240.	1.8	16
35	Features of Primary Chronic Headache in Children and Adolescents and Validity of Icdh 3 Criteria. <i>Frontiers in Neurology</i> , 2019, 10, 92.	1.1	19
36	Risk and Protective Environmental Factors Associated with Autism Spectrum Disorder: Evidence-Based Principles and Recommendations. <i>Journal of Clinical Medicine</i> , 2019, 8, 217.	1.0	71

#	ARTICLE	IF	CITATIONS
37	mTOR dysregulation and tuberous sclerosis-related epilepsy. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 185-201.	1.4	68
38	The Challenge of Pharmacotherapy in Children and Adolescents with Epilepsy-ADHD Comorbidity. <i>Clinical Drug Investigation</i> , 2018, 38, 1-8.	1.1	41
39	Everolimus for Retinal Astrocytic Hamartomas in Tuberous Sclerosis Complex. <i>Ophthalmology Retina</i> , 2018, 2, 257-260.	1.2	9
40	Syndrome of Transient Headache and Neurologic Deficits With Cerebrospinal Fluid Lymphocytosis Should Be Considered in Children Presenting With Acute Confusional State. <i>Headache</i> , 2018, 58, 438-442.	1.8	9
41	Clinical Features of Pediatric Idiopathic Intracranial Hypertension and Applicability of New ICHD-3 Criteria. <i>Frontiers in Neurology</i> , 2018, 9, 819.	1.1	10
42	Safety and tolerability profile of new antiepileptic drug treatment in children with epilepsy. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 1015-1028.	1.0	26
43	Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations. <i>European Journal of Paediatric Neurology</i> , 2018, 22, 738-748.	0.7	151
44	A clinical update on tuberous sclerosis complex-associated neuropsychiatric disorders (TAND). <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2018, 178, 309-320.	0.7	71
45	Everolimus Alleviates Obstructive Hydrocephalus due to Subependymal Giant Cell Astrocytomas. <i>Pediatric Neurology</i> , 2017, 68, 59-63.	1.0	15
46	Immediate and prolonged-release melatonin in children with neurodevelopmental disabilities. Author reply to Prof. Zisapel. <i>European Journal of Paediatric Neurology</i> , 2017, 21, 420-421.	0.7	3
47	Cognitive and behavioral effects of new antiepileptic drugs in pediatric epilepsy. <i>Brain and Development</i> , 2017, 39, 464-469.	0.6	97
48	New Perspectives in Autism Spectrum Disorder associated with Tuberous Sclerosis. <i>Journal of Pediatric Neurology</i> , 2017, 15, 123-128.	0.0	0
49	Current role of perampanel in pediatric epilepsy. <i>Italian Journal of Pediatrics</i> , 2017, 43, 51.	1.0	25
50	Metastatic Group 3 Medulloblastoma in a Patient With Tuberous Sclerosis Complex: Case Description and Molecular Characterization of the Tumor. <i>Pediatric Blood and Cancer</i> , 2016, 63, 719-722.	0.8	7
51	The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions. <i>Drugs</i> , 2016, 76, 551-565.	4.9	66
52	Combined targeted treatment in early onset epilepsy associated with tuberous sclerosis. <i>Epilepsy & Behavior Case Reports</i> , 2016, 5, 13-16.	1.5	4
53	Epilepsy in Tuberous Sclerosis Complex. <i>Journal of Pediatric Epilepsy</i> , 2016, 05, 064-069.	0.1	1
54	White matter disruption is associated with persistent seizures in tuberous sclerosis complex. <i>Epilepsy and Behavior</i> , 2016, 60, 63-67.	0.9	21

#	ARTICLE	IF	CITATIONS
55	Early onset epileptic encephalopathy or genetically determined encephalopathy with early onset epilepsy? Lessons learned from TSC. <i>European Journal of Paediatric Neurology</i> , 2016, 20, 203-211.	0.7	49
56	Toward targeted treatments in tuberous sclerosis. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 243-253.	0.5	1
57	Peri-ictal water drinking: a rare automatic behaviour in temporal lobe epilepsy. <i>Epileptic Disorders</i> , 2015, 17, 384-396.	0.7	10
58	Neurological and neuropsychiatric aspects of tuberous sclerosis complex. <i>Lancet Neurology</i> , The, 2015, 14, 733-745.	4.9	437
59	Reduction in retinal nerve fiber layer thickness in tuberous sclerosis complex. <i>Child's Nervous System</i> , 2015, 31, 857-861.	0.6	4
60	Paediatric use of melatonin (Author reply to D. J. Kennaway). <i>European Journal of Paediatric Neurology</i> , 2015, 19, 491-493.	0.7	8
61	Genotype/Phenotype Correlations in Tuberous Sclerosis Complex. <i>Seminars in Pediatric Neurology</i> , 2015, 22, 259-273.	1.0	96
62	Mammalian Target of Rapamycin Inhibitors and Life-Threatening Conditions in Tuberous Sclerosis Complex. <i>Seminars in Pediatric Neurology</i> , 2015, 22, 282-294.	1.0	16
63	Current role of melatonin in pediatric neurology: Clinical recommendations. <i>European Journal of Paediatric Neurology</i> , 2015, 19, 122-133.	0.7	219
64	Cognitive development in females with PCDH19 gene-related epilepsy. <i>Epilepsy and Behavior</i> , 2015, 42, 36-40.	0.9	32
65	Timing and Clinical Characteristics of Topiramate-Induced Psychosis in a Patient With Epilepsy and Tuberous Sclerosis. <i>Clinical Neuropharmacology</i> , 2014, 37, 38-39.	0.2	5
66	Long-term follow-up in children with benign convulsions associated with gastroenteritis. <i>European Journal of Paediatric Neurology</i> , 2014, 18, 572-577.	0.7	30
67	Rufinamide for the treatment of refractory epilepsy secondary to neuronal migration disorders. <i>Epilepsy Research</i> , 2014, 108, 542-546.	0.8	18
68	Headache and attention deficit and hyperactivity disorder in children: Common condition with complex relation and disabling consequences. <i>Epilepsy and Behavior</i> , 2014, 32, 72-75.	0.9	31
69	Current role of rufinamide in the treatment of childhood epilepsy: Literature review and treatment guidelines. <i>European Journal of Paediatric Neurology</i> , 2014, 18, 685-690.	0.7	32
70	Is mTOR inhibition a systemic treatment for tuberous sclerosis?. <i>Italian Journal of Pediatrics</i> , 2013, 39, 57.	1.0	46
71	mTOR inhibitors as a new therapeutic option for epilepsy. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 627-638.	1.4	43
72	Clinical Reasoning: A girl presenting with stiffness episodes during sleep, café-au-lait spots, and flecked retina. <i>Neurology</i> , 2013, 80, e42-6.	1.5	0

#	ARTICLE	IF	CITATIONS
73	Pancreatic Neuroendocrine Tumor in a Child with a Tuberous Sclerosis Complex 2 (TSC2) Mutation. <i>Endocrine Practice</i> , 2013, 19, e124-e128.	1.1	16
74	mTOR Inhibitors in Tuberous Sclerosis Complex. <i>Current Neuropharmacology</i> , 2012, 10, 404-415.	1.4	106
75	Ketogenic diet in early myoclonic encephalopathy due to non ketotic hyperglycinemia. <i>European Journal of Paediatric Neurology</i> , 2012, 16, 509-513.	0.7	47
76	Management of epilepsy associated with tuberous sclerosis complex (TSC): Clinical recommendations. <i>European Journal of Paediatric Neurology</i> , 2012, 16, 582-586.	0.7	178
77	Rufinamide efficacy and safety as adjunctive treatment in children with focal drug resistant epilepsy: The first Italian prospective study. <i>Epilepsy Research</i> , 2012, 102, 94-99.	0.8	14
78	mTOR Inhibitors in Tuberous Sclerosis Complex. <i>Current Neuropharmacology</i> , 2012, 10, 404-415.	1.4	64
79	Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis. <i>Epilepsy and Behavior</i> , 2011, 22, 735-739.	0.9	120
80	Autism in tuberous sclerosis: are risk factors identifiable and preventable?. <i>Future Neurology</i> , 2011, 6, 451-454.	0.9	3
81	The management of subependymal giant cell tumors in tuberous sclerosis: a clinician's perspective. <i>Child's Nervous System</i> , 2011, 27, 1203-1210.	0.6	54
82	Can we change the course of epilepsy in tuberous sclerosis complex?. <i>Epilepsia</i> , 2010, 51, 1330-1331.	2.6	3
83	Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges. <i>Child's Nervous System</i> , 2010, 26, 1495-1504.	0.6	48
84	Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. <i>European Journal of Paediatric Neurology</i> , 2010, 14, 146-149.	0.7	176
85	Attention deficit hyperactivity disorder in children with epilepsy. <i>Brain and Development</i> , 2010, 32, 10-16.	0.6	104
86	The neurobiological basis of ADHD. <i>Italian Journal of Pediatrics</i> , 2010, 36, 79.	1.0	117
87	Tubers, epileptogenic foci, and epileptogenic networks in tuberous sclerosis. <i>Epilepsia</i> , 2010, 51, 2357-2359.	2.6	3
88	Autism Spectrum Disorders in Tuberous Sclerosis: Pathogenetic Pathways and Implications for Treatment. <i>Journal of Child Neurology</i> , 2010, 25, 873-880.	0.7	76
89	Vagus Nerve Stimulation for Refractory Epilepsy in Tuberous Sclerosis. <i>Pediatric Neurology</i> , 2010, 43, 29-34.	1.0	49
90	Neuroimaging findings of Sturge-Weber Syndrome in a child with Tuberous Sclerosis. <i>Brain and Development</i> , 2009, 31, 352-355.	0.6	5

#	ARTICLE	IF	CITATIONS
91	Recent advances in neurobiology of Tuberous Sclerosis Complex. Brain and Development, 2009, 31, 104-113.	0.6	191
92	The neurobiology of attention deficit/hyperactivity disorder. European Journal of Paediatric Neurology, 2009, 13, 299-304.	0.7	102
93	Syndromic autism: causes and pathogenetic pathways. World Journal of Pediatrics, 2009, 5, 169-176.	0.8	77
94	Pharmacotherapy of idiopathic generalized epilepsies. Expert Opinion on Pharmacotherapy, 2009, 10, 5-17.	0.9	6
95	Attention-Deficit Hyperactivity Disorder (ADHD) and Tuberous Sclerosis Complex. Journal of Child Neurology, 2009, 24, 1282-1287.	0.7	45
96	Abnormal parieto-motor connectivity in Tuberous Sclerosis Complex. Epilepsy Research, 2009, 87, 102-105.	0.8	8
97	From the New Diagnostic Criteria to COVID-19 Pandemic Passing Through the Placebo Effect. What Have We Learned in the Management of Pediatric Migraine Over the Past 5 Years?. Frontiers in Neurology, 0, 13, .	1.1	0
98	Interictal Cognitive Performance in Children and Adolescents With Primary Headache: A Narrative Review. Frontiers in Neurology, 0, 13, .	1.1	2